Abstract Library

#3852 Novel insights to study the potential of the somatostatin system in NETs and NECs

Introduction: Neuroendocrine tumors (NETs) and carcinomas (NECs) are a heterogeneous group of cancers with increasing incidence worldwide. Surgery is the only curative choice, whereas an effective pharmacological approach for disseminated disease is still lacking. Somatostatin (SS) receptors (SSTs) provide a suitable pharmacological target to treat NETs with SS analogues (SSAs). However, a large proportion of NETs and, particularly most NECs, are unresponsive or resistant to SSAs. The underlying causes remain poorly understood and alternative strategies are needed. Recently, cortistatin (CST), a neuropeptide analogue of SS with comparable affinity to SSTs, emerged as an anti-inflammatory player, with potential antitumoral features.

Conference:

Presenting Author: Mangili F

Authors: Mangili F, Moreno Montilla M, García Vioque V, Blázquez-Encinas R, Mantovani G,

Keywords: PanNET, PanNEC, Somatostatin receptor (SST), cortistatin, Somatostatin,

#1998 Vitamin D, Bone Mineral Density and Fracture Risk Assessment in Patients with Neuroendocrine Tumors

Introduction: Some papers have recently described an association between neuroendrocrine tumors (NET) and both vitamin D deficiency (VDD) and low bone mineral density (BMD). The ten-year risk of osteoporotic fractures can be calculated with the FRAX algorithm.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grimaldi F

Authors: Grimaldi F, Kara E, Vanin F, Carpentieri M, Cipri C,

Keywords: neuroendocrine tumors, vitamin D deficiency, osteoporosis, bone mineral density, net,